Verrica Pharmaceuticals

First patient treated in Lytix Biopharma's Phase II NeoLIPA trial at Radiumhospitalet, Oslo, evaluating LTX-315 in early-stage melanoma patients. The trial combines LTX-315 with standard immunotherapy (pembrolizumab) before surgery, aiming to improve pathologic complete response rates and prevent disease recurrence. Expected interim results in H2 2025.

UroGen Pharma announces Q3 2024 financial results, including $25.2M in JELMYTO net product sales. The FDA accepted the New Drug Application for UGN-102 with a PDUFA target action date of June 13, 2025. UroGen reported $254.2M in cash, cash equivalents, and marketable securities as of September 30, 2024. A conference call and webcast will be held on November 6, 2024, at 10:00 AM ET.

Lytix Biopharma initiates Phase II NeoLIPA trial treating early-stage melanoma patients with LTX-315 and pembrolizumab before surgery, aiming to improve pathologic complete response rates and prevent disease recurrence.

Lytix Biopharma presents positive LTX-315 data at 2024 Fall Clinical Dermatology Conference, showing 51% tumor cell elimination in BCC patients, with 86% tumor size reduction and no serious adverse events. Verrica Pharmaceuticals plans to finalize Phase II study in H1 2025 and discuss next steps with FDA.

Philadelphia-area life sciences industry nears 900 layoffs since 2022 due to reduced investment and focus on late-stage development, with companies like Verrica Pharmaceuticals and Spark Therapeutics cutting jobs.

VP-315, an oncolytic peptide, showed promising results in reducing tumor size in basal cell carcinoma patients, with 86% experiencing tumor reduction and 51% achieving complete histological clearance. No dose-limiting toxicities were reported, and the agent is being explored as a non-surgical treatment option.

Acelyrin's izokibep phase III trial for HS met its primary endpoint; refocused pipeline strategy prioritizes lonigutamab for TED. Verrica's phase II study for basal cell carcinoma showed promising results, yet stock plunged. US Fed Circuit reinstated Viberzi patents. Ascentage advances lisaftoclax into fourth phase III for MDS treatment.

Verrica Pharmaceuticals Inc. announced a $125M term loan, with $50M available immediately, expected to close this week. YCANTH™, the first FDA-approved treatment for molluscum, targets a highly contagious skin infection affecting 6M people annually in the U.S., primarily children. Verrica plans to make YCANTH™ available by September 2023.